MC

501.4

+2.82%↑

SANES

8.074

-0.76%↓

SAF

287.1

-0.59%↓

BBVA

15.525

-2.02%↓

BNP

76.46

-0.31%↓

MC

501.4

+2.82%↑

SANES

8.074

-0.76%↓

SAF

287.1

-0.59%↓

BBVA

15.525

-2.02%↓

BNP

76.46

-0.31%↓

MC

501.4

+2.82%↑

SANES

8.074

-0.76%↓

SAF

287.1

-0.59%↓

BBVA

15.525

-2.02%↓

BNP

76.46

-0.31%↓

MC

501.4

+2.82%↑

SANES

8.074

-0.76%↓

SAF

287.1

-0.59%↓

BBVA

15.525

-2.02%↓

BNP

76.46

-0.31%↓

MC

501.4

+2.82%↑

SANES

8.074

-0.76%↓

SAF

287.1

-0.59%↓

BBVA

15.525

-2.02%↓

BNP

76.46

-0.31%↓

Search

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

174.4 -0.99

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

173.35

Max

176.85

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-23M

93M

Pardavimai

400K

745M

P/E

Sektoriaus vid.

75.693

27.333

Pelnas, tenkantis vienai akcijai

1.18

Dividendų pajamingumas

0.39

Pelno marža

12.43

Darbuotojai

10,030

EBITDA

-55M

201M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+26.36% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.39%

3.62%

Kitas uždarbis

2025-10-16

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2.8B

17B

Ankstesnė atidarymo kaina

175.39

Ankstesnė uždarymo kaina

174.4

Naujienos nuotaikos

By Acuity

31%

69%

138 / 535 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-27 22:51; UTC

Uždarbis

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H Rev $4.01B

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H Adj EPS $1.84

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H EPS $1.82

2025-08-27 23:50; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

2025-08-27 23:39; UTC

Uždarbis

Correction to Nvidia Earnings Article -- WSJ

2025-08-27 22:59; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-08-27 22:59; UTC

Rinkos pokalbiai

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

2025-08-27 22:58; UTC

Uždarbis

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

2025-08-27 22:57; UTC

Uždarbis

South32 FY Free Cash Flow $192 Million

2025-08-27 22:56; UTC

Uždarbis

South32 FY Total Capital Expenditure $1.35 Billion

2025-08-27 22:56; UTC

Uždarbis

South32 FY Capital Expenditure $963 Million, Excluding EAIs

2025-08-27 22:55; UTC

Uždarbis

South32 Net Cash $123 Million at June 30

2025-08-27 22:54; UTC

Uždarbis

South32: Focused on Maintaining Strong Operating Momentum

2025-08-27 22:53; UTC

Uždarbis

South32: $144 Million Remains to be Returned to Shareholders Under Program

2025-08-27 22:53; UTC

Uždarbis

South32 Extends Capital Management Program for 12 Months

2025-08-27 22:52; UTC

Uždarbis

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

2025-08-27 22:51; UTC

Uždarbis

South32 FY Revenue $5.78 Billion, Up 17% On-Year

2025-08-27 22:51; UTC

Uždarbis

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

2025-08-27 22:50; UTC

Uždarbis

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

2025-08-27 22:50; UTC

Uždarbis

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

2025-08-27 22:45; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

2025-08-27 22:44; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

2025-08-27 22:44; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

2025-08-27 22:43; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

2025-08-27 22:43; UTC

Uždarbis

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

2025-08-27 22:42; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

2025-08-27 22:42; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

2025-08-27 22:40; UTC

Uždarbis

Sandfire Resources Net Debt $123 Million at June 30

2025-08-27 22:40; UTC

Uždarbis

Sandfire Resources FY Underlying Ebitda $527.7 Million

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

26.36% į viršų

12 mėnesių prognozė

Vidutinis 221.44 EUR  26.36%

Aukščiausias 240 EUR

Žemiausias 174 EUR

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

6

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

138 / 535 reitingas Finansų sektorius

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.